EUVIMEDEUVIMED entdecken
ÜbersichtsarbeitOpen Access · CC BY 4.0

Targeting Hdm2 and Hdm4 in Anticancer Drug Discovery: Implications for Checkpoint Inhibitor Immunotherapy

Monde Ntwasa iD

Cells · 2024

DOI: 10.3390/cells13131124 ↗

Kurz gefasst

Übersichtsarbeit in der Zeitschrift Cells, 2024. Verfasst von Monde Ntwasa. Beteiligte Einrichtung: Department of Life and Consumer Sciences, University of South Africa, Cnr Pioneer Road and Christiaan de Wet Road, Florida, Johannesburg 1710, South …. Hauptthemen laut MEDLINE: Proto-Oncogene Proteins c-mdm2, Immunotherapy, Immune Checkpoint Inhibitors, Antineoplastic Agents. Die Arbeit wurde bisher 1-mal zitiert (Crossref) und nennt 76 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0).

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Hdm2 and Hdm4 are structural homologs that regulate the tumor suppressor protein, p53. Since some tumors express wild-type p53, Hdm2 and Hdm4 are plausible targets for anticancer drugs, especially in tumors that express wild-type p53. Hdm4 can enhance and antagonize the activity of Tp53, thereby playing a critical role in the regulation of p53’s activity and stability. Moreover, Hdm2 and Hdm4 are overexpressed in many cancers, some expressing wild-type Tp53. Due to experimental evidence suggesting that the activation of wild-type Tp53 can augment the antitumor activity by some checkpoint inhibitors, drugs targeting Hdm2 and Hdm4 may be strong candidates for combining with checkpoint inhibitor immunotherapy. However, other evidence suggests that the overexpression of Hdm2 and Hdm4 may indicate poor response to immune checkpoint inhibitors. These findings require careful examination and scrutiny. In this article, a comprehensive analysis of the Hdm2/Hdm4 partnership will be conducted. Furthermore, this article will address the current progress of drug development regarding molecules that target the Hdm2/Hdm4/Tp53 partnership.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Proto-Oncogene Proteins c-mdm2ImmunotherapyImmune Checkpoint InhibitorsAntineoplastic AgentsDrug DiscoveryHumansNeoplasmsTumor Suppressor Protein p53Cell Cycle ProteinsAnimalsProto-Oncogene Proteins

Stichwörter der Autor:innen

Hdm2Hdm4anticancer drugscancerimmune checkpoint inhibitorsoncology

Substanzen

Proto-Oncogene Proteins c-mdm2MDM2 protein, humanImmune Checkpoint InhibitorsAntineoplastic AgentsMDM4 protein, humanTumor Suppressor Protein p53Cell Cycle ProteinsProto-Oncogene Proteins

Autor:innen und Institutionen

  • Department of Life and Consumer Sciences, University of South Africa, Cnr Pioneer Road and Christiaan de Wet Road, Florida, Johannesburg 1710, South Africa.

ORCID-Profile: Monde Ntwasa

Zitieren

APA

Ntwasa, M. (2024). Targeting Hdm2 and Hdm4 in Anticancer Drug Discovery: Implications for Checkpoint Inhibitor Immunotherapy. Cells. https://doi.org/10.3390/cells13131124

Vancouver

Ntwasa M. Targeting Hdm2 and Hdm4 in Anticancer Drug Discovery: Implications for Checkpoint Inhibitor Immunotherapy. Cells. 2024. doi:10.3390/cells13131124

BibTeX
@article{Ntwasa2024,
  author = {Ntwasa, Monde},
  title = {Targeting Hdm2 and Hdm4 in Anticancer Drug Discovery: Implications for Checkpoint Inhibitor Immunotherapy},
  journal = {Cells},
  year = {2024},
  doi = {10.3390/cells13131124}
}
Kostenlos starten →